Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in lupin

Lupin, Glenmark, Dr Reddy's Recall Products In US

According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019

Read More

Lupin Recalls 4,113 Cartons Of Oral Contraceptive Medicine In US Market

The affected lot has been produced at the company's Pithampur-based manufacturing facility in Madhya Pradesh and distributed in the US by Baltimore-based Lupin Pharmaceuticals, Inc.

Read More

Lupin Announces Launch Of Its Diagnostics Business

The core facilities of the laboratory include all major diagnostics services, preventive health checkups, and a comprehensive range of tests.

Read More

Sun Pharma, Lupin Recall Products In US Market, Says USFDA

New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, has initiated the Class III nationwide (US) recall of the 10-count blister packs on October 12 this year.

Read More

Lupin To Acquire Australia-Based Southern Cross Pharma

This will significantly increase Lupin's value proposition and market share in the Australian market

Read More

Lupin Launches Generic Antifungal Product In US Market

Tavaborole Topical Solution is generic equivalent of Anacor Pharmaceuticals' Kerydin Topical Solution and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Read More

Lupin Arm Gets Supplemental New Drug Application Approval From USFDA For Solosec

Shares of Lupin Ltd closed at Rs 1,146.25 per scrip on BSE, down 0.26 per cent from its previous close.

Read More

Lupin Gets USFDA Nod To Market Sevelamer Hydrochloride Tablets

Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Read More

Lupin Gets UK Marketing Authorisation For Generic Pressurised Metered Dose Inhaler

Shares of Lupin Ltd were trading at Rs 1,195.20 per scrip on BSE, down 2.85 per cent from its previous close.

Read More

Lupin Gets Warning Letter From USFDA For Somerset Facility

Lupin is committed to addressing the concerns raised by the USFDA and will work with the FDA and the New Jersey district to resolve these issues at the earliest

Read More

Lupin Launches Digital Asthma Educator Platform

The new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.

Read More

Lupin Launches Generic Inhalation Product In US Market

Shares of Lupin were trading 0.39 per cent up at Rs 1,237.20 apiece on the BSE.

Read More

Lupin To Enter Digital Healthcare Space In India

Shares of Lupin Ltd were trading 0.29 per cent lower at Rs 1,243.30 apiece on BSE.

Read More

Lupin Reports 18 % Increase In Q4 Net Profit At Rs 460 Cr; FY21 Profit At Rs 1,216 Cr

The drug firm noted that its capital expenditure for the fourth quarter stood at Rs 140 crore and for the full year (FY21) at Rs 628 crore.

Read More

Lupin, Sun Pharma, Jubilant Cadista Recall Drugs In US Market

The affected lot has been produced by Jubilant Generics at its Roorkee based plant in Uttarakhand and marketed in the US by Salisbury-based Jubilant Cadista Pharmaceuticals, Inc.

Read More